The Actinic Keratosis Treatment Market is expected to register a CAGR of 5.3% during the forecast period. Actinic keratosis is a rough and often bumpy patch or lesion that forms on the skin. This condition sometimes called solar keratosis or senile keratosis which enlarges slowly and usually causes no signs or symptoms other than a patch or small spot on the skin. These patches take years to develop, usually first appearing in people over 40 years of age. Actinic keratosis is more common in older people with pale-colored eyes, fair skin, and red or blonde hair who burn easily and do not tan well. Some actinic keratosis may develop into an invasive form of skin cancer called squamous cell carcinoma (SCC). Progression of squamous cell carcinoma (SCC) may be indicated by growth, discomfort/tenderness, and persistent ulceration or bleeding.
According to a study report by J. Welzel et al., published in British Journal of Dermatology 2019, estimates more than 50% of the light‐skinned population is affected with actinic keratosis during their lifetime. Actinic keratosis is the third most common factor for United States patients to consult a dermatologist. In addition, as per the Skin Cancer Foundation, more than 15,000 Americans die each year from squamous cell carcinoma.
Furthermore, increasing prevalence of actinic keratosis, growing demand for minimally invasive procedures and increasing research and development for development of novel therapies are the key driving factors in actinic keratosis treatment market.
Key Market Trends
Topical Medications Segment is Expected to Hold a Major Market Share in the Actinic Keratosis Treatment Market
The topical medications segment holds a significant market share in the actinic keratosis treatment market and is anticipated to show a similar trend over the forecast period due to the easy availability of products, high target specificity and have a lower risk of scarring. Some of the US Food and Drug Administration (FDA) approved medications for the treatment of actinic keratoses are topical fluorouracil, imiquimod, diclofenac, ingenol mebutate, and combination treatment with medications. As per study report published in British Medical Journal 2019, in England, the prevalence of actinic keratoses was about 15% in men and 5.9% in women above 40 years of age, this prevalence was elevated to 34.1% and 18.2% for men and women, respectively, in patients older than 70 years. Actinic keratosis is considered precancerous because a cutaneous squamous cell carcinoma may arise from actinic keratosis. As the number of actinic keratosis increases the chance of developing squamous cell carcinoma increases. Furthermore, promising pipeline drugs and high adoption of combination treatment are the key driving factors in the topical medications segment.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
North America is expected to hold a major market share in the global actinic keratosis treatment market due to growing awareness about the occurrence of actinic keratosis and associated risk of squamous cell carcinoma in this region. According to the American Academy of Dermatology Association, estimates that more than 40 million Americans develop actinic keratoses (AKs) each year. In addition, about 60% of the Americans above 40 years of age, actinic keratosis is predisposed to develop having at least 1 actinic keratosis lesion. Furthermore, the presence of well-established healthcare infrastructure and increasing healthcare spending is also fueling the growth of the overall regional market to a large extent.
The Actinic Keratosis Treatment Market is Consolidated competitive and consists of a few major players. Some of the prominent players operating in the actinic keratosis treatment market are Bausch Health Companies Inc, LEO Pharma A/S, Almirall, S.A., Biofrontera AG, Sun Pharmaceutical Industries Limited, 3M Company, Galderma SA, Alma Lasers, Novartis AG and Hill Dermaceuticals, Inc.
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1.2 Scope of the Study
4.2 Market Drivers
4.2.1 Increasing Prevalence of Actinic Keratosis Worldwide
4.2.2 Growing Demand for Minimally Invasive Procedures
4.2.3 Favorable Reimbursement Policies
4.3 Market Restraints
4.3.1 Risk Factors Associated With Available Treatment Options
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1.1 Topical Medications
184.108.40.206 Ingenol Mebutate
220.127.116.11 Other Medications
18.104.22.168 Photodynamic Therapy
22.214.171.124 Other Procedures
5.2 By End User
5.2.1 Hospitals and Oncology Centers
5.2.2 Dermatology Clinics
5.2.3 Other End users
5.3.1 North America
126.96.36.199 United States
188.8.131.52 United Kingdom
184.108.40.206 Rest of Europe
220.127.116.11 South Korea
18.104.22.168 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
22.214.171.124 South Africa
126.96.36.199 Rest of Middle-East and Africa
5.3.5 South America
188.8.131.52 Rest of South America
6.1.1 Bausch Health Companies Inc
6.1.2 LEO Pharma A/S
6.1.3 Almirall, S.A.
6.1.4 Biofrontera AG
6.1.5 Sun Pharmaceutical Industries Limited
6.1.6 3M Company
6.1.7 Galderma SA
6.1.8 Alma Lasers
6.1.9 Novartis AG
6.1.10 Hill Dermaceuticals, Inc
A selection of companies mentioned in this report includes:
- Bausch Health Companies Inc
- LEO Pharma A/S
- Almirall, S.A.
- Biofrontera AG
- Sun Pharmaceutical Industries Limited
- 3M Company
- Galderma SA
- Alma Lasers
- Novartis AG
- Hill Dermaceuticals, Inc